6XB3.F Biophytis S.A.
- Market cap
- EUR 8.16M
- P/E
- -
- P/B
- 2.94x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is 6XB3.F undervalued?
Graham numberThe Graham number of Biophytis S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biophytis S.A. fundamental analysis
No fundamental analysis for Biophytis S.A. yet.
Biophytis S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It …
Full company profileBiophytis S.A. financial statements
Biophytis S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -26.8M | -23.3M | -14.3M | -8.50M |
| EBITDA | -30.3M | -22.8M | -15.1M | -9.32M |
| Net Income | -31.2M | -24.2M | -17.0M | - |
| EPS | -92 | -41 | -6.55 | - |
| Balance Sheet | ||||
| Total Assets | 34.9M | 22.0M | 12.0M | 6.90M |
| Total Liabilities | 29.1M | 23.9M | 15.8M | 16.6M |
| Shareholders' Equity | 5.84M | -1.88M | -3.86M | -9.67M |
| Cash & Short-term Investments | 23.9M | 11.1M | 5.57M | 78.0K |
| Cash Flow | ||||
| Operating Cash Flow | -23.8M | -19.0M | -12.9M | -8.64M |
| Capital Expenditure | 344K | 141K | 220K | 0.00 |
| Free Cash Flow | -24.1M | -19.1M | -13.1M | -8.64M |
| Ratios | ||||
| ROE | -534.1% | - | - | - |
| ROA | -89.4% | -110.1% | -142.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Biophytis S.A. dividends
Biophytis S.A. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:400 on May 3, 2024.
Who owns Biophytis S.A.
- Insiders 0.47%
- Institutions 0.49%
- Public & others 99.04%
- Shares outstanding 385M
- Free float 23.4M
Biophytis S.A. company profile
- Company name
- Biophytis S.A.
- Ticker
- 6XB3.F
- ISIN
- FR001400OLP5
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- 14 avenue de l'Opéra, Paris, France, 75001
- Website
- biophytis.com
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
Biophytis S.A. management
7- Mr. Stanislas Veillet Ph.D.Chairman of the Board & CEO · born 1965
- Mr. Christophe CourtillatChief Financial Officer
- Mr. Waly Dioh Ph.D.Chief Operating Officer · born 1969
- Dr. Pierre J. Dilda Ph.D.Chief Scientific Officer · born 1970
- Dr. Rene LafontScientific Advisor & Member of Scientific Advisory Board · born 1946
- Mr. Edouard BiethChief Strategy Officer · born 1981
- Ms. . TeylanFinancial Controller